CHICAGO, Sept. 11, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Infinity Pharmaceuticals (Nasdaq:INFI-Free Report), Keryx Biopharmaceuticals (Nasdaq:KERX-Free Report), Gilead (Nasdaq:GILD-Free Report) and Amgen (Nasdaq:AMGN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
AbbVie (NYSE:ABBV-Free Report) was in the news last week thanks to its agreements with Infinity Pharmaceuticals (Nasdaq:INFI-Free Report) and Calico. Keryx Biopharmaceuticals (Nasdaq:KERX-Free Report) was also in the headlines – the company's shares declined despite receiving FDA approval for its oral, ferric iron-based compound. Gilead (Nasdaq:GILD-Free Report) was in the news as well, once again due to its hepatitis C virus (HCV) treatment, Sovaldi.
Recap of the Week's Most Important Stories
1. AbbVie was very active on the deal making front last week with the company signing agreements with Infinity Pharma and Calico (the Google-backed life sciences company). The Infinity Pharma deal could see AbbVie shelling out up to $805 million in the form of upfront and milestone payments. The agreement is focused on experimental cancer treatment, duvelisib. AbbVie, which will be acquiring Shire, is looking to reduce its dependence on Humira and expand its portfolio (read more: Will AbbVie's $805 Million Agreement for Duvelisib Pay Off?).
2. Keryx saw its shares sliding despite receiving FDA approval for ferric citrate, its oral, ferric iron-based compound. Shares were down reflecting concerns regarding the product labeling which may curtail uptake (read more: Keryx Falls after Ferric Citrate's Approval with Warnings).
3. Prana Biotechnology's shares were up on news that the company has gained orphan drug status in the U.S. for its experimental Huntington disease treatment, PBT2. This means that the company will enjoy seven years of market exclusivity for PBT2 in the treatment of Huntington disease. The company will get other incentives as well (read more: Prana Biotechnology Up on Orphan Drug Status for PBT2).
4. Gilead is rumored to be close to sealing a deal under which its high-priced HCV treatment, Sovaldi, will be provided at a huge discount to 80 developing countries including India and Pakistan. According to a Bloomberg report, Sovaldi could be sold for as less as $900 for a 12-week course. This is in stark contrast to the drug's $84,000 price tag in the U.S. for the same period of treatment. Gilead's shares were down on concerns that this steep discount may once again lead to questions being raised about the drug's high price tag in the U.S. (read more: Gilead Down on Likely Sovaldi Generic Deal in Poor Nations).
5. Amgen (Nasdaq:AMGN-Free Report), which has made significant progress with its pipeline this year, has filed for EU approval of its PCSK9 inhibitor, evolocumab. Evolocumab is one of the most important candidates in Amgen's pipeline and represents huge commercial potential, once approved and launched. The company had filed for U.S. approval just a few days back (Read more: Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on ABBV - FREE
Get the full Report on INFI - FREE
Get the full Report on KERX - FREE
Get the full Report on GILD - FREE
Get the full Report on AMGN - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
SOURCE Zacks Investment Research, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article